Title: 1) Founder; 2) Senior Clinical Operations Consultant
Company: 1) Repress Therapeutics LLC; 2) NM Clinical Consulting LLC
Location: Volcano, California, United States
Shelly McCurry, Founder at Repress Therapeutics LLC and Senior Clinical Operations Consultant at NM Clinical Consulting LLC, has been recognized by Marquis Who’s Who Top Engineers for dedication, achievements and leadership in Oncology and Regenerative Medicine Clinical Research.
Ms. McCurry has established herself as a leading expert in clinical research, with a particular focus on oncology and regenerative medicine. Over the course of 15 years, she has demonstrated exceptional proficiency in early-phase oncology development and has contributed significantly to advancements in other therapeutic areas, including liver disease. Ms. McCurry’s expertise encompasses all phases of clinical research, from phase I to phase IV trials, and she has played a pivotal role in securing U.S. Food and Drug Administration approvals for hepatitis C products.
In 2024, Ms. McCurry founded Repress Therapeutics LLC, where she serves as its founder. Through this enterprise, she assists various pharmaceutical companies with clinical trial management while directing research and development efforts related to the molecular mechanisms of tumor suppression and stem cell regeneration. Ms. McCurry’s overarching goal is to discover a cure for cancer and promote wound healing through stem cell regeneration.
Since 2020, Ms. McCurry has also served as a senior clinical operations consultant at NM Clinical Consulting LLC. Specializing in biotechnology research, she provides strategic guidance to clients navigating complex clinical trial processes.
From 2019 to 2021, Ms. McCurry was a senior clinical trial manager at Apollomics in Foster City, California, following her tenure as clinical trial manager at the company’s Pleasanton, California, location between 2018 and 2019. During these years, she managed critical oncology studies and contributed to advancing novel cancer therapeutics.
Ms. McCurry also honed her skills as a clinical trial manager at Gilead Sciences in Foster City from 2016 to 2018, where she oversaw the operational aspects of global investigator-sponsored research and collaborative study research programs. Earlier, she served as a clinical trial associate at Acerta Pharma LLC, a member of the AstraZeneca Group, in Redwood City, California, from 2015 to 2016.
Among her earlier experiences, Ms. McCurry worked at Bioclinica in Newark, California, where she served as a clinical project coordinator in 2014 and a clinical project manager from 2014 to 2015. She also worked as an independent consultant with Cosmos Consulting – Theoretical Physics in Menlo Park, California, between 2012 and 2015, and as a research associate at Genentech in South San Francisco from 2012 to 2013. Ms. McCurry’s initial work took place at Harvard Medical School in Boston in 2011 as a clinical research scientist.
Ms. McCurry completed her undergraduate studies at the University of California, Santa Cruz, earning a Bachelor of Science in molecular, cell and developmental biology in 2008. She then earned a master’s degree in biotechnology with a professional science emphasis from San José State University in 2011. To further enhance her qualifications, Ms. McCurry obtained a certificate in clinical trial design and management from UCSC Extension between 2014 and 2016.
A defining moment in Ms. McCurry’s career occurred during her internship at the Stanford University School of Medicine from 2010 to 2011. Selected as one of only 10 students for a prestigious bridge program, she participated in a transformative research fellowship funded by a grant. Under the mentorship of esteemed scientists at Stanford, Ms. McCurry developed advanced laboratory skills and co-authored a publication on Wnt signaling and stem cell regeneration, a milestone that profoundly influenced her scientific trajectory.
Ms. McCurry has since co-authored several influential publications that have advanced understanding within oncology and regenerative medicine. Her most recent included the co-authorship of “A Phase 1 Study of APL-501, an Anti-PD-1 Antibody, in Patients with Recurrent or Advanced Solid Tumors,” published online by ASCO in 2020. Other publications in which Ms. McCurry has been published include Nature Communications, Gastrointestinal Endoscopy and Gastroenterology.
Driven by an intrinsic love for science and molecular biology, Ms. McCurry entered the field of clinical research, determined to make meaningful contributions to human health. Throughout her career, she has attributed her success to diligence, resilience and passion for science. Eager for the future, Ms. McCurry plans to integrate educational initiatives into Repress Therapeutics LLC. She remains committed to advancing scientific discovery while fostering educational growth within her community, an approach that underscores both her professional excellence and dedication to empowering future generations through science education.
For more information, please visit:
Contact Ms. McCurry: